EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieOpen Access · CC BY 4.0

Imipenem/cilastatin/relebactam dosing regimen justification using exposure–efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study

Munjal Patel iD, Garrett Nieddu, C Andrew DeRyke iD, Katherine Young, Luke Francis Chen, Amanda Paschke, Matthew L Rizk iD, Ferdous Gheyas

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01313-25 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Munjal Patel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Cilastatin, Healthcare-Associated Pneumonia. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An exposure–efficacy analysis of the phase 3 RESTORE-IMI 2 study ( NCT02493764 ) evaluated the relationship between plasma exposure of imipenem and relebactam and key efficacy endpoints (primary: 28-day all-cause mortality [ACM]; secondary: clinical response at early follow-up [EFU; 7–14 days after the end of treatment]) in adult participants with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) who received imipenem/cilastatin/relebactam 500/500/250 mg (IMI/REL). Participants from the IMI/REL treatment group in the microbiological-modified intent-to-treat population who had pharmacokinetic (PK) data and relevant baseline pathogen susceptibility data available were included ( N = 211). Previously developed population PK models were used to derive steady-state imipenem and relebactam exposures. Exposures were analyzed against the primary and secondary endpoints overall and by the most common key pathogens identified during RESTORE-IMI 2 ( Pseudomonas aeruginosa , Klebsiella pneumoniae , Acinetobacter calcoaceticus–baumannii complex, and Escherichia coli ). Most participants (82.0%; n = 168/205) achieved the imipenem exposure target, and 83.9% ( n = 177/211) achieved the relebactam exposure target. ACM was 16.1% overall; 11% among participants who met the imipenem exposure target, and 18% among those who met the relebactam exposure target. At EFU, 62.1% of participants experienced a favorable clinical response. Efficacy was similar across the overall exposure range and by key pathogens. There were no apparent trends in ACM rates by imipenem or relebactam exposure distributions overall or by individual key pathogens, suggesting an exposure–efficacy plateau. These results further support the recommended and currently approved IMI/REL 500/500/250 mg dosing regimen for patients with HABP/VABP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsCilastatinHealthcare-Associated PneumoniaImipenemPneumonia, BacterialPneumonia, Ventilator-AssociatedAdultAgedFemaleHumansMaleMiddle Agedbeta-Lactamase InhibitorsCilastatin, Imipenem Drug CombinationDrug CombinationsEscherichia coliKlebsiella pneumoniaeMicrobial Sensitivity TestsPseudomonas aeruginosa

Stichwörter der Autor:innen

exposure–efficacyimipenemnosocomial pneumoniapharmacokineticsrelebactam

Substanzen

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCilastatinCilastatin, Imipenem Drug CombinationDrug CombinationsImipenemrelebactam

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Munjal Patel, C Andrew DeRyke, Matthew L Rizk

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA

Zitieren

APA

Patel, M., Nieddu, G., DeRyke, C. A., Young, K., Chen, L. F., Paschke, A., Rizk, M. L., & Gheyas, F. (2026). Imipenem/cilastatin/relebactam dosing regimen justification using exposure–efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01313-25

Vancouver

Patel M, Nieddu G, DeRyke CA, Young K, Chen LF, Paschke A, et al. Imipenem/cilastatin/relebactam dosing regimen justification using exposure–efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01313-25

BibTeX
@article{Patel2026,
  author = {Patel, Munjal and Nieddu, Garrett and DeRyke, C Andrew and Young, Katherine and Chen, Luke Francis and Paschke, Amanda and Rizk, Matthew L and Gheyas, Ferdous},
  title = {Imipenem/cilastatin/relebactam dosing regimen justification using exposure–efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01313-25}
}
Kostenlos starten →